PARP Inhibition in the Treatment of Pancreatic Cancer: Current and Future Perspectives on Personalized Therapy

Download this slideset on the current advances and evolving landscape of PARP inhibitors for patients with pancreatic cancer.
Dirk Arnold, MD, PhD
person default
Michel Ducreux, MD, PhD
Philip Agop Philip, MD, PhD, FRCP
Format: Microsoft PowerPoint (.ppt)
File Size: 882 KB
Released: December 14, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca

Related Content

Results from NAPOLI 3 trial of first-line NALIRIFOX vs gemcitabine + nab-paclitaxel in mPDAC, presented at ASCO GI 2023 as reported by Clinical Care Options (CCO)

Released: January 30, 2023

In slides from Clinical Care Options (CCO), experts provide perspectives on updates in biomarker testing and targeted therapy across GI cancers

John L. Marshall, MD
Program Director
Christopher H. Lieu, MD Manish A. Shah, MD
Released: January 19, 2023

Experts highlight key studies being presented at the upcoming 2023 ASCO GI annual meeting in this commentary from Clinical Care Options (CCO)

Christopher H. Lieu, MD Rachna Shroff, MD, MS Released: January 19, 2023

Expert review of key data in GI cancers from the 2022 ASCO Annual Meeting, from Clinical Care Options (CCO)

Christopher H. Lieu, MD Rachna Shroff, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 31, 2022 Expired: August 30, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings